🚀 VC round data is live in beta, check it out!
Mirxes Holding Valuation Multiples
Discover revenue and EBITDA valuation multiples for Mirxes Holding and similar public comparables like OPKO Health, Novogene, Castle Biosciences, CareDx and more.
Mirxes Holding Overview
About Mirxes Holding
Mirxes Holding Co Ltd is a miRNA technology company that is making diagnostic solutions for the screening of diseases accessible across its key markets in Asia, including Singapore and China. It has one Core Product (namely, GASTROClearTM), two other commercialized products (namely, LUNGClearTM and FortitudeTM), and six product candidates at the pre-clinical stage, as illustrated in the chart below. GASTROClearTM, its Core Product, is a blood-based miRNA detection panel consisting of 12 miRNA biomarkers for gastric cancer screening. The company generates the majority of its revenue from Singapore.
Founded
2020
HQ
Employees
352
Website
Sectors
Financials (FY)
EV
$816M
Mirxes Holding Financials
Mirxes Holding reported last fiscal year revenue of $20M and negative EBITDA of ($71M).
In the same fiscal year, Mirxes Holding generated $9M in gross profit, ($71M) in EBITDA losses, and had net loss of ($92M).
Mirxes Holding P&L
In the most recent fiscal year, Mirxes Holding reported revenue of $20M and EBITDA of ($71M).
Mirxes Holding expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $20M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $9M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 44% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($71M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (348%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (332%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($92M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (455%) | XXX | XXX | XXX |
| Net Debt | — | — | $19M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Mirxes Holding Stock Performance
Mirxes Holding has current market cap of $896M, and enterprise value of $816M.
Market Cap Evolution
Mirxes Holding's stock price is $3.00.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $816M | $896M | 0.0% | XXX | XXX | XXX | $-0.31 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMirxes Holding Valuation Multiples
Mirxes Holding trades at 40.2x EV/Revenue multiple, and (11.6x) EV/EBITDA.
Mirxes Holding Financial Valuation Multiples
As of March 7, 2026, Mirxes Holding has market cap of $896M and EV of $816M.
Equity research analysts estimate Mirxes Holding's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Mirxes Holding has a P/E ratio of (9.7x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $896M | XXX | $896M | XXX | XXX | XXX |
| EV (current) | $816M | XXX | $816M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 40.2x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (11.6x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (12.1x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 91.9x | XXX | XXX | XXX |
| P/E | — | XXX | (9.7x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (25.9x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Mirxes Holding Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Mirxes Holding Margins & Growth Rates
Mirxes Holding's revenue in the last fiscal year declined by (16%).
Mirxes Holding Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (16%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (348%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 52% | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 38% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 52% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 94% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 376% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Mirxes Holding Public Comps
See public comps and valuation multiples for other Diagnostics & Genomics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| OPKO Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Novogene | XXX | XXX | XXX | XXX | XXX | XXX |
| Castle Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| CareDx | XXX | XXX | XXX | XXX | XXX | XXX |
| Personalis | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Mirxes Holding M&A Activity
Mirxes Holding acquired XXX companies to date.
Last acquisition by Mirxes Holding was on XXXXXXXX, XXXXX. Mirxes Holding acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Mirxes Holding
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialMirxes Holding Investment Activity
Mirxes Holding invested in XXX companies to date.
Mirxes Holding made its latest investment on XXXXXXXX, XXXXX. Mirxes Holding invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Mirxes Holding
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Mirxes Holding
| When was Mirxes Holding founded? | Mirxes Holding was founded in 2020. |
| Where is Mirxes Holding headquartered? | Mirxes Holding is headquartered in Singapore. |
| How many employees does Mirxes Holding have? | As of today, Mirxes Holding has over 352 employees. |
| Is Mirxes Holding publicly listed? | Yes, Mirxes Holding is a public company listed on HKEX. |
| What is the stock symbol of Mirxes Holding? | Mirxes Holding trades under 02629 ticker. |
| When did Mirxes Holding go public? | Mirxes Holding went public in 2025. |
| Who are competitors of Mirxes Holding? | Mirxes Holding main competitors are OPKO Health, Novogene, Castle Biosciences, CareDx. |
| What is the current market cap of Mirxes Holding? | Mirxes Holding's current market cap is $896M. |
| What is the current revenue of Mirxes Holding? | Mirxes Holding's last fiscal year revenue is $20M. |
| What is the current EV/Revenue multiple of Mirxes Holding? | Current revenue multiple of Mirxes Holding is 40.2x. |
| Is Mirxes Holding profitable? | No, Mirxes Holding is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.